Search

Your search keyword '"Bertsch, U."' showing total 251 results
Start Over Author "Bertsch, U."
251 results on '"Bertsch, U."'

1. Identification of novel genetic loci for risk of multiple myeloma by functional annotation.

Author

Macauda, A., Briem, K., Clay-Gilmour, A., Cozen, W., Försti, A., Giaccherini, M., Corradi, C., Sainz, J., Niazi, Y., Horst, R. ter, Li, Y., Netea, M.G., Vogel, U., Hemminki, K., Slager, S.L., Varkonyi, J., Andersen, V., Iskierka-Jazdzewska, E., Mártinez-Lopez, J., Zaucha, J., Camp, N.J., Rajkumar, S.V., Druzd-Sitek, A., Bhatti, P., Chanock, S.J., Kumar, S.K., Subocz, E., Mazur, G., Landi, S., Machiela, M.J., Jerez, A., Norman, A.D., Hildebrandt, M.A., Kadar, K., Berndt, S.I., Ziv, E., Buda, G., Nagler, A., Dumontet, C., Raźny, M., Watek, M., Butrym, A., Grzasko, N., Dudzinski, M., Rybicka-Ramos, M., Matera, E.L., García-Sanz, R., Goldschmidt, H., Jamroziak, K., Jurczyszyn, A., Clavero, E., Giles, G.G., Pelosini, M., Zawirska, D., Kruszewski, M., Marques, H., Haastrup, E., Sánchez-Maldonado, J.M., Bertsch, U., Rymko, M., Raab, M.S., Brown, E.E., Hofmann, J.N., Vachon, C., Campa, D., Canzian, F., Macauda, A., Briem, K., Clay-Gilmour, A., Cozen, W., Försti, A., Giaccherini, M., Corradi, C., Sainz, J., Niazi, Y., Horst, R. ter, Li, Y., Netea, M.G., Vogel, U., Hemminki, K., Slager, S.L., Varkonyi, J., Andersen, V., Iskierka-Jazdzewska, E., Mártinez-Lopez, J., Zaucha, J., Camp, N.J., Rajkumar, S.V., Druzd-Sitek, A., Bhatti, P., Chanock, S.J., Kumar, S.K., Subocz, E., Mazur, G., Landi, S., Machiela, M.J., Jerez, A., Norman, A.D., Hildebrandt, M.A., Kadar, K., Berndt, S.I., Ziv, E., Buda, G., Nagler, A., Dumontet, C., Raźny, M., Watek, M., Butrym, A., Grzasko, N., Dudzinski, M., Rybicka-Ramos, M., Matera, E.L., García-Sanz, R., Goldschmidt, H., Jamroziak, K., Jurczyszyn, A., Clavero, E., Giles, G.G., Pelosini, M., Zawirska, D., Kruszewski, M., Marques, H., Haastrup, E., Sánchez-Maldonado, J.M., Bertsch, U., Rymko, M., Raab, M.S., Brown, E.E., Hofmann, J.N., Vachon, C., Campa, D., and Canzian, F.

Abstract

Contains fulltext : 299996.pdf (Publisher’s version ) (Open Access), 01 november 2023

Published
2023

2. P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL

Author

Mai, E. K., primary, Bertsch, U., additional, Fenk, R., additional, Tichy, D., additional, Besemer, B., additional, Dürig, J., additional, Schroers, R., additional, von Metzler, I., additional, Hänel, M., additional, Mann, C., additional, Asemissen, A. M., additional, Heilmeier, B., additional, Nievergall, E., additional, Huhn, S., additional, Kriegsmann, K., additional, Weinhold, N., additional, Luntz, S., additional, Holderrried, T. A. W., additional, Trautmann-Grill, K., additional, Gezer, D., additional, Klaiber-Hakimi, M., additional, Müller, M., additional, Khandanpour, C., additional, Knauf, W., additional, Scheid, C., additional, Munder, M., additional, Geer, T., additional, Riesenberg, H., additional, Thomalla, J., additional, Hoffmann, M., additional, Raab, M. S., additional, Salwender, H. J., additional, Weisel, K. C., additional, and Goldschmidt, H., additional

Published
2022
Full Text
View/download PDF

3. P879: EXENT AND FLC MASS SPECTROMETRY FOR SEROLOGICAL IDENTIFICATION AND QUANTIFICATION OF MONOCLONAL IMMUNOGLOBULINS IN MULTIPLE MYELOMA

Author

Huhn, S., primary, Poos, A. M., additional, Mai, E. K., additional, Hänel, M., additional, Salwender, H. J., additional, Dürig, J., additional, Blau, I. W., additional, Scheid, C., additional, Weisel, K. C., additional, Munder, M., additional, Berlanga, O., additional, Bertsch, U., additional, Goldschmidt, H., additional, and Weinhold, N., additional

Published
2022
Full Text
View/download PDF

4. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

Author

Mai, E K, Bertsch, U, Dürig, J, Kunz, C, Haenel, M, Blau, I W, Munder, M, Jauch, A, Schurich, B, Hielscher, T, Merz, M, Huegle-Doerr, B, Seckinger, A, Hose, D, Hillengass, J, Raab, M S, Neben, K, Lindemann, H-W, Zeis, M, Gerecke, C, Schmidt-Wolf, I G H, Weisel, K, Scheid, C, Salwender, H, and Goldschmidt, H

Published
2015
Full Text
View/download PDF

9. MCT1 as molecularly validated predictive marker for lenalidomide-maintenance therapy in multiple myeloma

Author

Stroh, J., Seckinger, A., Heider, M., Eichner, R., Schick, M., Slawska, J., Emde, M., Salwender, H., Bertsch, U., Goldschmidt, H., Weisel, K., Scheid, C., Keller, U., Hose, D., Bassermann, F., Stroh, J., Seckinger, A., Heider, M., Eichner, R., Schick, M., Slawska, J., Emde, M., Salwender, H., Bertsch, U., Goldschmidt, H., Weisel, K., Scheid, C., Keller, U., Hose, D., and Bassermann, F.

Published
2020

11. Bortezomib before and after high-dose chemotherapy improves the survival in patients with newly diagnosed multiple myeloma and renal insufficiency - a subgroup analysis of the prospective randomised GMMG HD4/HOVON 65 study: V817

Author

Scheid, C., Sonneveld, P., Schmidt-Wolf, I., van der Holt, B., Hielscher, T., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Hänel, M., Vellenga, E., Schubert, J., Blau, I. W., Jie, A., van de Velde, H., Peter, N., Schaafsma, M., Lindemann, W., Kersten, M. J., Duehrsen, U., Delforge, M., Weisel, K., Croockewit, S., Martin, H., Wittebol, S., Schouten, H., van Marwijk-Kooy, M., Wijermans, P., Lokhorst, H. M., and Goldschmidt, H.

Published
2011

13. Bortezomib during induction and maintenance before and after autologous transplantation improves overall survival in patients with renal impairment: subgroup analysis from the HOVON-65/GMMG-HD4 randomized trial for newly diagnosed multiple myeloma: O270

Author

Scheid, C., Sonneveld, P., Schmidt-Wolf, I., van der Holt, B., Hielscher, T., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Hänel, M., Vellenga, E., Schubert, J., Blau, I. W., Jie, A., van de Velde, H., Peter, N., Schaafsma, M., Lindemann, W., Kersten, M., Duehrsen, U., Delforge, M., Weisel, K., Croockewit, S., Martin, H., Wittebol, S., Schouten, H., van Marwijk-Kooy, M., Wijermans, P., Lokhorst, H., and Goldschmidt, H.

Published
2011

20. First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) vs. VAD as Induction Treatment Prior to High-dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM): B152

Author

Sonneveld, P, Eljarari, L, Salwender, H, Zweegman, S, Vellenga, E, Van Der Holt, B, Schmidt-Wolf, I GH, Bertsch, U, Schubert, J, Blau, I W, Jie, G SK, Beverloo, B, Jauch, A, Hose, D, Schaafsma, R, Kersten, M J, Delforge, M, De Weerdt, O, Van Der Griend, R, Wijermans, P W, Martin, H, Van Der Velde, H, Lokhorst, H M, and Goldschmidt, H

Published
2009

25. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Author

Went, M, Sud, A, Försti, A, Halvarsson, BM, Weinhold, N, Kimber, S, van Duin, M, Thorleifsson, G, Holroyd, A, Johnson, DC, Li, N, Orlando, G, Law, PJ, Ali, M, Chen, B, Mitchell, JS, Gudbjartsson, DF, Kuiper, R, Stephens, OW, Bertsch, U, Broderick, P, Campo, C, Bandapalli, OR, Einsele, H, Gregory, WA, Gullberg, U, Hillengass, J, Hoffmann, P, Jackson, GH, Jöckel, KH, Johnsson, E, Kristinsson, SY, Mellqvist, UH, Nahi, H, Easton, D, Pharoah, P, Dunning, A, Peto, J, Canzian, F, Swerdlow, A, Eeles, RA, Kote-Jarai, ZS, Muir, K, Pashayan, N, Nickel, J, Nöthen, MM, Rafnar, T, Ross, FM, da Silva Filho, MI, Thomsen, H, Turesson, I, Vangsted, A, Andersen, NF, Waage, A, Walker, BA, Wihlborg, AK, Broyl, A, Davies, FE, Thorsteinsdottir, U, Langer, C, Hansson, M, Goldschmidt, H, Kaiser, M, Sonneveld, P, Stefansson, K, Morgan, GJ, Hemminki, K, Nilsson, B, Houlston, RS, Henderson, BE, Haiman, CA, Benlloch, S, Schumacher, FR, Olama, AAA, Berndt, SI, Conti, DV, Wiklund, F, Chanock, S, Stevens, VL, Tangen, CM, The PRACTICAL Consortium, and Claessens, Frank

Subjects
Male, Quality Control, Risk, Chromatin Immunoprecipitation, Genotype, European Continental Ancestry Group, Quantitative Trait Loci, Bayes Theorem, Polymorphism, Single Nucleotide, Chromatin, Gene Expression Regulation, Humans, Female, Genetic Predisposition to Disease, Multiple Myeloma, Promoter Regions, Genetic, Genome-Wide Association Study
Abstract

© 2018, The Author(s). Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous GWAS and a replication series, totalling 9974 MM cases and 247,556 controls of European ancestry. Collectively, these data provide evidence for six new MM risk loci, bringing the total number to 23. Integration of information from gene expression, epigenetic profiling and in situ Hi-C data for the 23 risk loci implicate disruption of developmental transcriptional regulators as a basis of MM susceptibility, compatible with altered B-cell differentiation as a key mechanism. Dysregulation of autophagy/apoptosis and cell cycle signalling feature as recurrently perturbed pathways. Our findings provide further insight into the biological basis of MM. ispartof: Nature Communications vol:9 issue:1 ispartof: location:England status: published

Published
2018

26. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (vol 9, 3707, 2018)

Author

Went, M, Sud, A, Foersti, A, Halvarsson, B-M, Weinhold, N, Kimber, S, van Duin, M, Thorleifsson, G, Holroyd, A, Johnson, DC, Li, N, Orlando, G, Law, PJ, Ali, M, Chen, B, Mitchell, JS, Gudbjartsson, DF, Kuiper, R, Stephens, OW, Bertsch, U, Broderick, P, Campo, C, Bandapalli, OR, Einsele, H, Gregory, WA, Gullberg, U, Hillengass, J, Hoffmann, P, Jackson, GH, Joeckel, K-H, Johnsson, E, Kristinsson, SY, Mellqvist, U-H, Nahi, H, Easton, D, Pharoah, P, Dunning, A, Peto, J, Canzian, F, Swerdlow, A, Eeles, RA, Kote-Jarai, Z, Muir, K, Pashayan, N, Henderson, BE, Haiman, CA, Benlloch, S, Schumacher, FR, Al Olama, AA, Berndt, SI, Conti, DV, Wiklund, F, Chanock, S, Stevens, VL, Tangen, CM, Batra, J, Clements, J, Gronberg, H, Schleutker, J, Albanes, D, Weinstein, S, Wolk, A, West, C, Mucci, L, Cancel-Tassin, G, Koutros, S, Sorensen, KD, Grindedal, EM, Neal, DE, Hamdy, FC, Donovan, JL, Travis, RC, Hamilton, RJ, Ingles, SA, Rosenstein, B, Lu, Y-J, Giles, GG, Kibel, AS, Vega, A, Kogevinas, M, Penney, KL, Park, JY, Stanford, JL, Cybulski, C, Nordestgaard, BG, Brenner, H, Maier, C, Kim, J, John, EM, Teixeira, MR, Neuhausen, SL, De Ruyck, K, Razack, A, Newcomb, LF, Lessel, D, Kaneva, R, Usmani, N, Claessens, F, Townsend, PA, Gago-Dominguez, M, Roobol, MJ, Menegaux, F, Khaw, K-T, Cannon-Albright, L, Pandha, H, Thibodeau, SN, Nickel, J, Noethen, MM, Rafnar, T, Ross, FM, Filho, MIDS, Thomsen, H, Turesson, I, Vangsted, A, Andersen, NF, Waage, A, Walker, BA, Wihlborg, A-K, Broyl, A, Davies, FE, Thorsteinsdottir, U, Langer, C, Hansson, M, Goldschmidt, H, Kaiser, M, Sonneveld, P, Stefansson, K, Morgan, GJ, Hemminki, K, Nilsson, B, Houlston, RS, Went, M, Sud, A, Foersti, A, Halvarsson, B-M, Weinhold, N, Kimber, S, van Duin, M, Thorleifsson, G, Holroyd, A, Johnson, DC, Li, N, Orlando, G, Law, PJ, Ali, M, Chen, B, Mitchell, JS, Gudbjartsson, DF, Kuiper, R, Stephens, OW, Bertsch, U, Broderick, P, Campo, C, Bandapalli, OR, Einsele, H, Gregory, WA, Gullberg, U, Hillengass, J, Hoffmann, P, Jackson, GH, Joeckel, K-H, Johnsson, E, Kristinsson, SY, Mellqvist, U-H, Nahi, H, Easton, D, Pharoah, P, Dunning, A, Peto, J, Canzian, F, Swerdlow, A, Eeles, RA, Kote-Jarai, Z, Muir, K, Pashayan, N, Henderson, BE, Haiman, CA, Benlloch, S, Schumacher, FR, Al Olama, AA, Berndt, SI, Conti, DV, Wiklund, F, Chanock, S, Stevens, VL, Tangen, CM, Batra, J, Clements, J, Gronberg, H, Schleutker, J, Albanes, D, Weinstein, S, Wolk, A, West, C, Mucci, L, Cancel-Tassin, G, Koutros, S, Sorensen, KD, Grindedal, EM, Neal, DE, Hamdy, FC, Donovan, JL, Travis, RC, Hamilton, RJ, Ingles, SA, Rosenstein, B, Lu, Y-J, Giles, GG, Kibel, AS, Vega, A, Kogevinas, M, Penney, KL, Park, JY, Stanford, JL, Cybulski, C, Nordestgaard, BG, Brenner, H, Maier, C, Kim, J, John, EM, Teixeira, MR, Neuhausen, SL, De Ruyck, K, Razack, A, Newcomb, LF, Lessel, D, Kaneva, R, Usmani, N, Claessens, F, Townsend, PA, Gago-Dominguez, M, Roobol, MJ, Menegaux, F, Khaw, K-T, Cannon-Albright, L, Pandha, H, Thibodeau, SN, Nickel, J, Noethen, MM, Rafnar, T, Ross, FM, Filho, MIDS, Thomsen, H, Turesson, I, Vangsted, A, Andersen, NF, Waage, A, Walker, BA, Wihlborg, A-K, Broyl, A, Davies, FE, Thorsteinsdottir, U, Langer, C, Hansson, M, Goldschmidt, H, Kaiser, M, Sonneveld, P, Stefansson, K, Morgan, GJ, Hemminki, K, Nilsson, B, and Houlston, RS

Abstract

The original version of this Article contained an error in the spelling of a member of the PRACTICAL Consortium, Manuela Gago-Dominguez, which was incorrectly given as Manuela Gago Dominguez. This has now been corrected in both the PDF and HTML versions of the Article. Furthermore, in the original HTML version of this Article, the order of authors within the author list was incorrect. The PRACTICAL consortium was incorrectly listed after Richard S. Houlston and should have been listed after Nora Pashayan. This error has been corrected in the HTML version of the Article; the PDF version was correct at the time of publication.

Published
2019

27. PF597 HIGH DOSE MELPHALAN (200MG/M2) AND AUTOLOGOUS TRANSPLANTATION IN NEWLY-DIAGNOSED MULTIPLE MYELOMA UP TO THE AGE OF 70 YEARS: A SUBGROUP ANALYSIS FROM THE PHASE III GMMG-MM5 TRIAL

Author

Mai, E.K., primary, Miah, K., additional, Merz, M., additional, Dürig, J., additional, Scheid, C., additional, Weisel, K.C., additional, Kunz, C., additional, Bertsch, U., additional, Munder, M., additional, Lindemann, H.-W., additional, Hose, D., additional, Jauch, A., additional, Seckinger, A., additional, Luntz, S., additional, Sauer, S., additional, Fuhrmann, S., additional, Brossart, P., additional, Elmaagacli, A., additional, Goerner, M., additional, Bernhard, H., additional, Hoffmann, M., additional, Raab, M.S., additional, Blau, I.W., additional, Hänel, M., additional, Benner, A., additional, Salwender, H.J., additional, and Goldschmidt, H., additional

Published
2019
Full Text
View/download PDF

29. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Author

Went, M. (Molly), Sud, A. (Amit), Försti, A. (Asta), Halvarsson, B.-M. (Britt-Marie), Weinhold, N. (Niels), Kimber, S. (Scott), Duin, M. (Mark) van, Thorleifsson, G. (Gudmar), Holroyd, A. (Amy), Johnson, D.C. (David C.), Li, N. (Ni), Orlando, G. (Giulia), Law, P.J. (Philip J.), Ali, M. (Mina), Chen, B. (Bowang), Mitchell, J.S. (Jonathan S.), Gudbjartsson, D.F. (Daniel), Kuiper, R. (Ruud), Stephens, O.W. (Owen W.), Bertsch, U. (Uta), Broderick, P. (Peter), Campo, C. (Chiara), Bandapalli, O.R. (Obul R), Einsele, H. (Hermann), Gregory, W.A. (Walter A.), Gullberg, U. (Urban), Hillengass, J. (Jens), Hoffmann, P. (Per), Jackson, G.H. (Graham H.), JöCkel, K.-H. (Karl-Heinz), Johnsson, E. (Ellinor), Kristinsson, S.Y. (Sigurður Y.), Mellqvist, U.H. (U. H.), Nahi, H. (Hareth), Easton, D.F. (Douglas), Pharoah, P. (Paul), Dunning, A. (Alison), Peto, J. (Julian), Canzian, F. (Federico), Swerdlow, A.J. (Anthony ), Eeles, R.A. (Rosalind A.), Kote-Jarai, Z., Muir, K. (Kenneth), Pashayan, N. (Nora), Nickel, J. (Jolanta), Nöthen, M.M. (Markus), Rafnar, T. (Thorunn), Ross, F.M. (Fiona M.), da Silva Filho, M.I. (Miguel Inacio), Thomsen, H. (Hauke), Turesson, I. (I.), Vangsted, A. (Annette), Andersen, N.F. (Niels Frost), Waage, A. (Anders), Walker, B. (BrianA.), Wihlborg, A.-K. (Anna-Karin), Broyl, A. (Annemiek), Davies, F.E. (F.), Thorsteinsdottir, U. (Unnur), Langer, C. (Christian), Hansson, M. (Markus), Goldschmidt, H. (Hartmut), Kaiser, M.F. (Martin F.), Sonneveld, P. (Pieter), Zwart, J-A. (John-Anker), Morgan, G. (Gareth), Hemminki, K. (Kari), Nilsson, B. (Björn), Houlston, R.S. (Richard S.), Henderson, B.E. (Brian), Haiman, C.A. (Christopher), Benlloch, S. (Sara), Schumacher, F.R. (Fredrick R), Olama, A.A.A. (Ali Amin Al), Berndt, S.I. (Sonja), Conti, G. (Giario), Wiklund, F. (Fredrik), Chanock, S.J. (Stephen), Stevens, V.L. (Victoria L.), Tangen, C.M. (Catherine M.), Batra, J. (Jyotsna), Clements, J. (Judith), Grönberg, H. (Henrik), Schleutker, J. (Johanna), Albanes, D. (Demetrius), Weinstein, S. (Stephanie), Wolk, K. (Kerstin), West, C. (Catharine), Mucci, L. (Lorelei), Cancel-Tassin, G. (Géraldine), Koutros, S. (Stella), Sorensen, K.D. (Karina Dalsgaard), Grindedal, E.M. (Eli Marie), Neal, D.E. (David E.), Hamdy, F. (Freddie), Donovan, J.L. (Jenny L.), Travis, S.P.L. (Simon), Hamilton, R.J. (Robert J.), Ingles, S.A. (Sue), Rosenstein, B.S. (Barry S.), Lu, Y.-J. (Yong-Jie), Giles, G.G. (Graham G.), Kibel, A. (Adam), Vega, A. (Ana), Kogevinas, M. (Manolis), Penney, K.L. (Kathryn L.), Park, J.Y. (Jong Y.), Stanford, J.L. (Janet L.), Cybulski, C. (Cezary), Nordestgaard, B.G. (Børge), Brenner, H. (Hermann), Maier, C. (Christiane), Kim, J. (Jeri), John, E.M. (Esther), Teixeira, P.J., Neuhausen, S.L. (Susan), De Ruyck, K. (Kim), Razack, A. (Azad), Newcomb, L.F. (Lisa F.), Lessel, D. (Davor), Kaneva, R. (Radka), Usmani, N. (Nawaid), Claessens, F., Townsend, P.A. (Paul A.), Dominguez, M.G. (Manuela Gago), Roobol-Bouts, M.J. (Monique), Menegaux, F. (Florence), Khaw, K.-T. (Kay-Tee), Cannon-Albright, L.A. (Lisa), Pandha, H. (Hardev), Thibodeau, S.N. (Stephen N.), Went, M. (Molly), Sud, A. (Amit), Försti, A. (Asta), Halvarsson, B.-M. (Britt-Marie), Weinhold, N. (Niels), Kimber, S. (Scott), Duin, M. (Mark) van, Thorleifsson, G. (Gudmar), Holroyd, A. (Amy), Johnson, D.C. (David C.), Li, N. (Ni), Orlando, G. (Giulia), Law, P.J. (Philip J.), Ali, M. (Mina), Chen, B. (Bowang), Mitchell, J.S. (Jonathan S.), Gudbjartsson, D.F. (Daniel), Kuiper, R. (Ruud), Stephens, O.W. (Owen W.), Bertsch, U. (Uta), Broderick, P. (Peter), Campo, C. (Chiara), Bandapalli, O.R. (Obul R), Einsele, H. (Hermann), Gregory, W.A. (Walter A.), Gullberg, U. (Urban), Hillengass, J. (Jens), Hoffmann, P. (Per), Jackson, G.H. (Graham H.), JöCkel, K.-H. (Karl-Heinz), Johnsson, E. (Ellinor), Kristinsson, S.Y. (Sigurður Y.), Mellqvist, U.H. (U. H.), Nahi, H. (Hareth), Easton, D.F. (Douglas), Pharoah, P. (Paul), Dunning, A. (Alison), Peto, J. (Julian), Canzian, F. (Federico), Swerdlow, A.J. (Anthony ), Eeles, R.A. (Rosalind A.), Kote-Jarai, Z., Muir, K. (Kenneth), Pashayan, N. (Nora), Nickel, J. (Jolanta), Nöthen, M.M. (Markus), Rafnar, T. (Thorunn), Ross, F.M. (Fiona M.), da Silva Filho, M.I. (Miguel Inacio), Thomsen, H. (Hauke), Turesson, I. (I.), Vangsted, A. (Annette), Andersen, N.F. (Niels Frost), Waage, A. (Anders), Walker, B. (BrianA.), Wihlborg, A.-K. (Anna-Karin), Broyl, A. (Annemiek), Davies, F.E. (F.), Thorsteinsdottir, U. (Unnur), Langer, C. (Christian), Hansson, M. (Markus), Goldschmidt, H. (Hartmut), Kaiser, M.F. (Martin F.), Sonneveld, P. (Pieter), Zwart, J-A. (John-Anker), Morgan, G. (Gareth), Hemminki, K. (Kari), Nilsson, B. (Björn), Houlston, R.S. (Richard S.), Henderson, B.E. (Brian), Haiman, C.A. (Christopher), Benlloch, S. (Sara), Schumacher, F.R. (Fredrick R), Olama, A.A.A. (Ali Amin Al), Berndt, S.I. (Sonja), Conti, G. (Giario), Wiklund, F. (Fredrik), Chanock, S.J. (Stephen), Stevens, V.L. (Victoria L.), Tangen, C.M. (Catherine M.), Batra, J. (Jyotsna), Clements, J. (Judith), Grönberg, H. (Henrik), Schleutker, J. (Johanna), Albanes, D. (Demetrius), Weinstein, S. (Stephanie), Wolk, K. (Kerstin), West, C. (Catharine), Mucci, L. (Lorelei), Cancel-Tassin, G. (Géraldine), Koutros, S. (Stella), Sorensen, K.D. (Karina Dalsgaard), Grindedal, E.M. (Eli Marie), Neal, D.E. (David E.), Hamdy, F. (Freddie), Donovan, J.L. (Jenny L.), Travis, S.P.L. (Simon), Hamilton, R.J. (Robert J.), Ingles, S.A. (Sue), Rosenstein, B.S. (Barry S.), Lu, Y.-J. (Yong-Jie), Giles, G.G. (Graham G.), Kibel, A. (Adam), Vega, A. (Ana), Kogevinas, M. (Manolis), Penney, K.L. (Kathryn L.), Park, J.Y. (Jong Y.), Stanford, J.L. (Janet L.), Cybulski, C. (Cezary), Nordestgaard, B.G. (Børge), Brenner, H. (Hermann), Maier, C. (Christiane), Kim, J. (Jeri), John, E.M. (Esther), Teixeira, P.J., Neuhausen, S.L. (Susan), De Ruyck, K. (Kim), Razack, A. (Azad), Newcomb, L.F. (Lisa F.), Lessel, D. (Davor), Kaneva, R. (Radka), Usmani, N. (Nawaid), Claessens, F., Townsend, P.A. (Paul A.), Dominguez, M.G. (Manuela Gago), Roobol-Bouts, M.J. (Monique), Menegaux, F. (Florence), Khaw, K.-T. (Kay-Tee), Cannon-Albright, L.A. (Lisa), Pandha, H. (Hardev), and Thibodeau, S.N. (Stephen N.)

Abstract

Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous GWAS and a replication series, totalling 9974 MM cases and 247,556 controls of European ancestry. Collectively, these data provide evidence for six new MM risk loci, bringing the total number to 23. Integration of information from gene expression, epigenetic profiling and in situ Hi-C data for the 23 risk loci implicate disruption of developmental transcriptional regulators as a basis of MM susceptibility, compatible with altered B-cell differentiation as a key mechanism. Dysregulation of autophagy/apoptosis and cell cycle signalling feature as recurrently perturbed pathways. Our findings provide further insight i

Published
2018
Full Text
View/download PDF

30. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial

Author

Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., Kooy, M. van Marwijk, Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, Le, Salwender, H. J., Sonneveld, P., Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., Kooy, M. van Marwijk, Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, Le, Salwender, H. J., and Sonneveld, P.

Abstract

The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR) = 0.76, 95% confidence interval (95% CI) of 0.65-0.89, P = 0.001). Overall survival (OS) was similar in the PAD versus VAD arm (HR = 0.89, 95% CI: 0.74-1.08, P = 0.24). The incidence of SPM were similar between the two arms (7% each, P = 0.73). The negative prognostic effects of the cytogenetic aberration deletion 17p13 (clone size >= 10%) and renal impairment at baseline (serum creatinine > 2 mg dl(-1)) on PFS and OS remained abrogated in the PAD but not VAD arm. OS from first relapse/progression was similar between the study arms (HR = 1.02, P = 0.85). In conclusion, the survival benefit with BTZ induction/maintenance compared with classical cytotoxic agents and thalidomide maintenance is maintained without an increased risk of SPM.

Published
2018

31. MAGNETIC RESONANCE IMAGING BEFORE AND AFTER UPFRONT AUTOLOGOUS TRANSPLANTATION IDENTIFIES PATIENTS WITH ADVERSE OUTCOME BUT RESPONSE TO TREATMENT WITHIN THE PROSPECTIVE GMMG MM5 PHASE III TRIAL

Author

Merz, M., Hielscher, T., Seckinger, A., Jauch, A., Mai, E. K., Bertsch, U., Raab, M. S., Neben, K., Salwender, H., Blau, I. W., Lindemann, H. W., Duerig, J., Scheid, C., Haenel, M., Weisel, K., Delorme, S., Kauczor, H. U., Hose, D., Goldschmidt, H., Hillengass, J., Merz, M., Hielscher, T., Seckinger, A., Jauch, A., Mai, E. K., Bertsch, U., Raab, M. S., Neben, K., Salwender, H., Blau, I. W., Lindemann, H. W., Duerig, J., Scheid, C., Haenel, M., Weisel, K., Delorme, S., Kauczor, H. U., Hose, D., Goldschmidt, H., and Hillengass, J.

Published
2018

32. Bortezomib before and after high-dose therapy in myeloma : long-term results from the phase III HOVON-65/GMMG-HD4 trial

Author

Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, Sonneveld, P, Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, and Sonneveld, P

Published
2018

33. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

Author

Externen Hematologie, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, Sonneveld, P, Externen Hematologie, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, and Sonneveld, P

Published
2018

34. Prediction of early overall and infection-related mortality during induction therapy in transplant-eligible multiple myeloma - a pooled analysis from three GMMG phase III trials

Author

Mai, E. K., Hielscher, T., Bertsch, U., Schlenzka, J., Salwender, H. J., Munder, M., Gerecke, C., Pfreundschuh, M., Duehrsen, U., Brossart, P., Neben, K., Hillengass, J., Raab, M. S., Hose, D., Merz, M., Breitkreutz, I., Jauch, A., Martin, H., Lindemann, H. -W., Scheid, C., Weisel, K. C., Blau, I. W., Goldschmidt, H., Mai, E. K., Hielscher, T., Bertsch, U., Schlenzka, J., Salwender, H. J., Munder, M., Gerecke, C., Pfreundschuh, M., Duehrsen, U., Brossart, P., Neben, K., Hillengass, J., Raab, M. S., Hose, D., Merz, M., Breitkreutz, I., Jauch, A., Martin, H., Lindemann, H. -W., Scheid, C., Weisel, K. C., Blau, I. W., and Goldschmidt, H.

Published
2017

35. Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma

Author

Johnson, DC, Weinhold, N, Mitchell, JS, Chen, B, Kaiser, M, Begum, DB, Hillengass, J, Bertsch, U, Gregory, WA, Cairns, D, Jackson, GH, Försti, A, Nickel, J, Hoffmann, P, Nöethen, MM, Stephens, OW, Barlogie, B, Davis, FE, Hemminki, K, Goldschmidt, H, Houlston, RS, and Morgan, GJ

Abstract

Survival following a diagnosis of multiple myeloma (MM) varies between patients and some of these differences may be a consequence of inherited genetic variation. In this study, to identify genetic markers associated with MM overall survival (MM-OS), we conduct a meta-analysis of four patient series of European ancestry, totalling 3,256 patients with 1,200 MM-associated deaths. Each series is genotyped for ∼600,000 single nucleotide polymorphisms across the genome; genotypes for six million common variants are imputed using 1000 Genomes Project and UK10K as the reference. The association between genotype and OS is assessed by Cox proportional hazards model adjusting for age, sex, International staging system and treatment. We identify a locus at 6q25.1 marked by rs12374648 associated with MM-OS (hazard ratio=1.34, 95% confidence interval=1.22-1.48, P=4.69 × 10 -9). Our findings have potential clinical implications since they demonstrate that inherited genotypes can provide prognostic information in addition to conventional tumor acquired prognostic factors.

Published
2016

36. A new multiple myeloma classification system that correlates to disease stage and prognosis:Indication of reversible phenotypic plasticity as a hallmark

Author

Johnsen, Hans Erik, Bødker, Julie Støve, Schmitz, Alexander, Larsen, Steffen Falgreen, Perez-Andres, M., Samur, M. K., Davies, F., Pawlyn, C., Kaiser, M., Johnson, D., Bertsch, U., Broijl, A., van Duin, M., Shah, R., Kjeldsen, Malene Krag, Bergkvist, Kim Steve, Bilgrau, Anders Ellern, Johansen, Preben, El-Galaly, Tarec, Samworth, R., Sonneveld, P., Goldschmidt, H., Morgan, G. J., Orfao, A., Munshi, N, Dybkær, Karen, and Bøgsted, Martin

Published
2016

37. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

Author

Goldschmidt, H, primary, Lokhorst, H M, additional, Mai, E K, additional, van der Holt, B, additional, Blau, I W, additional, Zweegman, S, additional, Weisel, K C, additional, Vellenga, E, additional, Pfreundschuh, M, additional, Kersten, M J, additional, Scheid, C, additional, Croockewit, S, additional, Raymakers, R, additional, Hose, D, additional, Potamianou, A, additional, Jauch, A, additional, Hillengass, J, additional, Stevens-Kroef, M, additional, Raab, M S, additional, Broijl, A, additional, Lindemann, H W, additional, Bos, G M J, additional, Brossart, P, additional, van Marwijk Kooy, M, additional, Ypma, P, additional, Duehrsen, U, additional, Schaafsma, R M, additional, Bertsch, U, additional, Hielscher, T, additional, Jarari, Le, additional, Salwender, H J, additional, and Sonneveld, P, additional

Published
2017
Full Text
View/download PDF

38. Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach

Author

Went, M, primary, Sud, A, additional, Law, P J, additional, Johnson, D C, additional, Weinhold, N, additional, Försti, A, additional, van Duin, M, additional, Mitchell, J S, additional, Chen, B, additional, Kuiper, R, additional, Stephens, O W, additional, Bertsch, U, additional, Campo, C, additional, Einsele, H, additional, Gregory, W M, additional, Henrion, M, additional, Hillengass, J, additional, Hoffmann, P, additional, Jackson, G H, additional, Lenive, O, additional, Nickel, J, additional, Nöthen, M M, additional, da Silva Filho, M I, additional, Thomsen, H, additional, Walker, B A, additional, Broyl, A, additional, Davies, F E, additional, Langer, C, additional, Hansson, M, additional, Kaiser, M, additional, Sonneveld, P, additional, Goldschmidt, H, additional, Hemminki, K, additional, Nilsson, B, additional, Morgan, G J, additional, and Houlston, R S, additional

Published
2017
Full Text
View/download PDF

39. Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial

Author

Huhn, S, primary, Weinhold, N, additional, Nickel, J, additional, Pritsch, M, additional, Hielscher, T, additional, Hummel, M, additional, Bertsch, U, additional, Huegle-Doerr, B, additional, Vogel, M, additional, Angermund, R, additional, Hänel, M, additional, Salwender, H J, additional, Weisel, K, additional, Dürig, J, additional, Görner, M, additional, Kirchner, H, additional, Peter, N, additional, Graeven, U, additional, Lordick, F, additional, Hoffmann, M, additional, Reimer, P, additional, Blau, I W, additional, Jauch, A, additional, Dembowsky, K, additional, Möhler, T, additional, Wuchter, P, additional, and Goldschmidt, H, additional

Published
2017
Full Text
View/download PDF

40. Bortezomib induction and maintenance in patients with newly diagnosed multiple myeloma: long-term follow-up of the Hovon-65/GMMG-HD4 trial

Author

Sonneveld, P, Salwender, H-J, Van Der Holt, B, El Jarari, L, Bertsch, U, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, al., et, Anatomy and neurosciences, Hematology, CCA - Disease profiling, CCA - Innovative therapy, and CCA - Quality of life

Abstract

Background: We reported better PFS and OS in transplant eligible patients with newly diagnosed Multiple Myeloma (MM) who were treated with bortezomib during induction and maintenance, when compared with standard treatment in the HOVON-65/GMMG-HD4 trial. (P. Sonneveld et al., J Clin Oncol 30:2946-2955, 2012). Here the long-term follow up data are presented.Methods: 827 eligible patients were randomized to induction therapy with VAD (vincristine, doxorubicin, dexamethasone) or PAD (bortezomib, doxorubicin, dexamethasone) followed by high-dose melphalan (once or twice) and autologous stem cell transplant. Maintenance consisted of daily thalidomide (T) 50 mg (VAD arm) or 2-weekly bortezomib (B) 1.3 mg/m2 (PAD arm) for 2 years. The primary endpoint was progression-free survival (PFS) adjusted for ISS stage.Results: After a median follow up of 91.4 months (maximum 119) 410 patients are alive. Response rates were VAD/HDM/T: CR 25%, ≥VGPR 56%, ≥PR 83%; PAD/HDM/B: CR 37%, ≥VGPR 76%%, ≥PR 91%, The median duration of maintenance therapy was 14 months (thalidomide) and 23 months (bortezomib), respectively. Main reasons for discontinuation were toxicity (T: 31%; B: 11%), disease progression (T: 33%; B: 36%) or normal completion (T: 28%; B: 48%).Of 827 patients in the analysis, 206 are alive without progression/relapse. PFS was significantly better in the bortezomib arm, i.e. median 34 versus 28 months (HR=0.77, 95% CI=0.65-0.90, p=0.001). Median overall survival (OS) was 90 months in the bortezomib arm vs 83 months in the control arm, but 42% at 9 years in both arms. We used the restricted mean survival time (RMST) method to compare OS between the two treatment arms In univariate analysis. The difference in RMST8y was 4.8 months (95% CI 0.2-9.5, p=0.04) in favor of the bortezomib arm.A landmark analysis in patients who had received HDM starting at 12 months showed a significant PFS advantage of bortezomib in all patients (p=0.02), in patients in VGPR/PR (p=0.02) but not in CR (p=0.19). For OS there was no advantage for bortezomib in either group.PFS at 60 months in bortezomib treated patients was not different when single vs double HDM/ASCT was administered, i.e. 28% vs 27%. However, OS at 60 months was 71% vs 60% in favor of double HDM/ASCT (p=0.04). Subgroup analysis was performed based on presence/absence of adverse FISH (CA) in 395 patients treated with double HDM/ASCT. PFS at 60 months for each abnormality (CA or no CA) in bortezomib vs standard arm is given in Table 1 PFS at 60 months, %OS at 60 months, %FISHnBortezomib armpStandard armBortezomib armpStandard Armt(4;14) yes/no50/29516% vs 27%0.048% vs 24%52% vs 75%0.0133% vs 64%add(1q) yes/no113/23116% vs 32%0.00510% vs 28%57% vs 79%0.00143% vs 70%del(17p) yes/no39/31222% vs 27%0.475% vs 24%65% vs 72%0.4818% vs 66%Table 1. These data show that bortezomib treatment combined with double HDM/ASCT significantly improves PFS and OS in patients with del(17p) and almost abrogates the negative impact of this CA. In t(4;14) and add(1q) some improvement is observed, however the negative impact remains significant. In high-risk patients presenting with elevated creatinine >2 mg/dL bortezomib significantly improved PFS at 60 months (32% vs 5%) (p=0.001) and OS at 60 months (66% vs 21% months (p

Published
2015

41. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

Author

Merz, M., primary, Salwender, H., additional, Haenel, M., additional, Mai, E. K., additional, Bertsch, U., additional, Kunz, C., additional, Hielscher, T., additional, Blau, I. W., additional, Scheid, C., additional, Hose, D., additional, Seckinger, A., additional, Jauch, A., additional, Hillengass, J., additional, Raab, M. S., additional, Schurich, B., additional, Munder, M., additional, Brossart, P., additional, Gerecke, C., additional, Lindemann, H.-W., additional, Zeis, M., additional, Weisel, K., additional, Duerig, J., additional, and Goldschmidt, H., additional

Published
2016
Full Text
View/download PDF

42. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

Author

Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H., Goldschmidt, H., Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H., and Goldschmidt, H.

Abstract

We aimed at demonstrating non-inferiority of bortezomib/cyclophosphamide/dexamethasone (VCD) compared to bortezomib/doxorubicin/dexamethasone (PAd) induction therapy with respect to very good partial response rates or better (>= VGPR) in 504 newly diagnosed, transplant-eligible multiple myeloma patients. VCD was found to be non-inferior to PAd with respect to >= VGPR rates (37.0 versus 34.3%, P = 0.001). The rates of progressive disease (PD) were 0.4% (VCD) versus 4.8% (PAd; P = 0.003). In the PAd arm, 11 of 12 patients with PD had either renal impairment (creatinine >= 2 mg/dl) at diagnosis or the cytogenetic abnormality gain 1q21, whereas no PD was observed in these subgroups in the VCD arm. Leukocytopenia/neutropenia (>= 3 degrees) occurred more frequently in the VCD arm (35.2% versus 11.3%, P<0.001). Neuropathy rates (>= 2 degrees) were higher in the PAd group (14.9 versus 8.4%, P = 0.03). Serious adverse events, both overall and those related to thromboembolic events, were higher in the PAd group (32.7 versus 24.0%, P = 0.04 and 2.8 versus 0.4%, P = 0.04). Stem cell collection was not impeded by VCD. VCD is as effective as PAd in terms of achieving >= VGPR rates with fewer PD and has a favorable toxicity profile. Therefore, VCD is preferable to PAd as induction therapy.

Published
2015

43. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in newly-diagnosed multiple myeloma: final results from the GMMG-HD2 trial

Author

Mai, E. K., Benner, A., Bertsch, U., Schmidt-Wolf, I. G. H., Haenel, A., Kunzmann, V, Naumann, R., Neben, K., Egerer, G., Hillengass, J., Neubauer, A., Peyn, A., Ko, Y-D, Peter, N., Salwender, H. J., Scheid, C., Goldschmidt, H., Mai, E. K., Benner, A., Bertsch, U., Schmidt-Wolf, I. G. H., Haenel, A., Kunzmann, V, Naumann, R., Neben, K., Egerer, G., Hillengass, J., Neubauer, A., Peyn, A., Ko, Y-D, Peter, N., Salwender, H. J., Scheid, C., and Goldschmidt, H.

Published
2015

44. Comparative assessment of myeloma response to induction treatment in the GMMG MM5 study using IMWG criteria and hevylite assay

Author

Scheid, C., Hose, D., Bertsch, U., Hielscher, T., Kunz, C., Salwender, H., Haenel, M., Merz, M., Mai, E. K., Schurich, B., Munder, M., Schmidt-Wolf, I, Gerecke, C., Lindemann, W., Zeis, M., Weisel, K., Duerig, J., Jauch, A., Peters-Regehr, T., Zorn, M., Goldschmidt, H., Scheid, C., Hose, D., Bertsch, U., Hielscher, T., Kunz, C., Salwender, H., Haenel, M., Merz, M., Mai, E. K., Schurich, B., Munder, M., Schmidt-Wolf, I, Gerecke, C., Lindemann, W., Zeis, M., Weisel, K., Duerig, J., Jauch, A., Peters-Regehr, T., Zorn, M., and Goldschmidt, H.

Published
2015

45. Genetic factors influencing the risk of multiple myeloma bone disease

Author

Johnson, D C, primary, Weinhold, N, additional, Mitchell, J, additional, Chen, B, additional, Stephens, O W, additional, Försti, A, additional, Nickel, J, additional, Kaiser, M, additional, Gregory, W A, additional, Cairns, D, additional, Jackson, G H, additional, Hoffmann, P, additional, Noethen, M M, additional, Hillengass, J, additional, Bertsch, U, additional, Barlogie, B, additional, Davis, F E, additional, Hemminki, K, additional, Goldschmidt, H, additional, Houlston, R S, additional, and Morgan, G J, additional

Published
2015
Full Text
View/download PDF

46. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma

Author

Weinhold, N., primary, Kirn, D., additional, Seckinger, A., additional, Hielscher, T., additional, Granzow, M., additional, Bertsch, U., additional, Egerer, G., additional, Salwender, H., additional, Blau, I. W., additional, Weisel, K., additional, Hillengass, J., additional, Raab, M. S., additional, Hose, D., additional, Goldschmidt, H., additional, and Jauch, A., additional

Published
2015
Full Text
View/download PDF

47. Bortezomib during induction and maintenance before and after autologous transplantation improves overall survival in patients with renal impairment : subgroup analysis from the HOVON-65/GMMG-HD4 randomized trial for newly diagnosed multiple myeloma

Author

Scheid, C., Sonneveld, P., Schmidt-Wolf, I., van der Holt, B., Hielscher, T., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Hanel, M., Vellenga, E., Schubert, J., Blau, I. W., Jie, A., van de Velde, H., Peter, N., Schaafsma, M., Lindemann, W., Kersten, M., Dührsen, Ulrich, Delforge, M., Weisel, K., Croockewit, S., Martin, H., Wittebol, S., Schouten, H., van Marwijk-Kooy, M., Wijermans, P., Lokhorst, H., Goldschmidt, H., GMMG, and HOVON

Subjects
Medizin
Published
2011

48. Bortezomib before and after high-dose chemotherapy improves the survival in patients with newly diagnosed multiple myeloma and renal insufficiency - a subgroup analysis of the prospective randomised GMMG HD4/HOVON 65 study

Author

Scheid, C., Sonneveld, P., Schmidt-Wolf, I., van der Holt, B., Hielscher, T., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Hanel, M., Vellenga, E., Schubert, J., Blau, I. W., Jie, A., van de Velde, H., Peter, N., Schaafsma, M., Lindemann, W., Kersten, M. J., Dührsen, Ulrich, Delforge, M., Weisel, K., Croockewit, S., Martin, H., Wittebol, S., Schouten, H., van Marwijk-Kooy, M., Wijermans, P., Lokhorst, H. M., Goldschmidt, H., and GMMG HOVON

Subjects
Medizin
Published
2011

49. Multiple Myeloma Subtyping That Associates Normal B-Cell Subset Phenotypes, do Correlate to Disease Stage and Prognosis - Indication of Reversible Phenotypic Plasticity as a Hallmark

Author

Johnsen, H.E., primary, Bødker, J.S., additional, Schmitz, A., additional, Falgreen, S., additional, Perez-Andres, M., additional, Samur, M.K., additional, Davies, F., additional, Pawlyn, C., additional, Kaiser, M., additional, Johnson, D., additional, Bertsch, U., additional, Broijl, A., additional, van Duin, M., additional, Shah, R., additional, Kjeldsen, M.K., additional, Bergkvist, K.S., additional, Bilgrau, A.E., additional, Johansen, P., additional, El-Galaly, T.C., additional, Samworth, R., additional, Sonneveld, P., additional, Goldschmidt, H., additional, Morgan, G.J., additional, Orfao, A., additional, Munshi, N., additional, Dybkær, K., additional, and Bøgsted, M., additional

Published
2015
Full Text
View/download PDF

50. Experiences with bortezomib in multiple myeloma - from Phase II studies to daily practice

Author

Stefan Schmitt, Bertsch U, and Goldschmidt H

Subjects
Pharmacology, Oncology, medicine.medical_specialty, Bortezomib, business.industry, Antineoplastic Agents, medicine.disease, Boronic Acids, Clinical Trials, Phase II as Topic, Daily practice, Internal medicine, Pyrazines, medicine, Proteasome inhibitor, Humans, Pharmacology (medical), business, Multiple Myeloma, Multiple myeloma, medicine.drug
Published
2010

Catalog

Books, media, physical & digital resources
See catalog results